In addition, elevated ADAM17 levels correlated with reduced overall survival rates, and thus ADAM17 was found to be a significant biomarker for poor prognosis in GC [71,72,80,81,82] and shown to play an important role in the development and progression of this malignancy [81]. This evidence concerns the gene ADAM17 and gastric cancer.